CrowdStrike Holdings (CRWD)

Ciberseguridad / Software de plataforma

CrowdStrike compounds recurring revenue at 24% annually on a wide-moat platform, but stock-based compensation absorbs 23.1% of revenue: net of that cost, operating cash flow held flat around $0.52 billion between fiscal years 2024 and 2026, and owner earnings, already net of maintenance capex, fell from $0.43 to $0.36 billion between fiscal years 2024 and 2026 while revenue grew 57%, and only in the twelve months ended July 2026 do they rise to $0.57 billion. At 476× the price already pays for operating leverage that has not yet reached the shareholder; the estimated return is -24% annually and the verdict is Overvalued.

Moat Compounder estimates the intrinsic value of CrowdStrike Holdings (CRWD) at $66 per share on a five-year horizon. With the stock at $263.01 at 2026-10-12 close, the expected total return is -24.3% per year: overvalued. The analysis draws on Fiscal 2026 10-K and 8-K fiscal 2027 first-quarter results (guidance). Analysis dated 2026-08-27.

Price
$263.01
at 2026-10-12 close
Intrinsic value (5y, base)
$66
Total annual return (5y)
-24.3%
Status (nominal)
Overvalued
Margin of safety
No margin

The essentials

  • Annual recurring revenue of $5.84 billion growing 25%, with net dollar retention of 115% and more than 88,000 customer organizations
  • Stock-based compensation equals 23.1% of revenue and 77.3% of reported free cash flow: net of that cost, operating cash flow held flat around $0.52 billion, and owner earnings, already net of maintenance capex, fell from $0.43 to $0.36 billion between fiscal years 2024 and 2026
  • Fiscal year 2027 guidance raises net new annual recurring revenue growth to 34% at the midpoint and non-GAAP operating income to a range of $1,497.2 to $1,508.4 million
  • The July 19, 2024 incident is still costing money: an additional $82.4 million of general expenses in fiscal 2026, plus ongoing securities litigation and inquiries
  • At 476× on owner earnings, the estimated return is -24% annually and the verdict is Overvalued
Health: Under watch
Price $263 at 2026-10-12 closeMarket Cap $274.7 bnEnterprise Value $270.4 bnNet cash $4.3 bnEV/FCF maintenance (today) 475.5x

Intrinsic value — two valuation methods

No margin of safety
Price market
$263
DCF value today
$58
-78.1% vs price
Multiples value today
$53
-80.0% vs price

By both methods, the value today (DCF $58 · Multiples $53) is below the market price ($263).

Pillars of the analysis

The verdict — today vs 5 years

Today — expensive, no margin of safety: at $263 trades ~400.4% above its value discounted to today (~$53); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$33.

Thesis

The business

A subscription platform with a wide moat, net retention of 115%, and recurring revenue growing 24% annually. The model is capital-light — capex is 6% of revenue — and working capital works in its favor because the subscription is billed in advance. The quality of the business is not in question; what is in question is how much of that value reaches the shareholder.

The valuation

Valued by a multiple on owner earnings: operating cash flow net of stock-based compensation, less maintenance capex. The netting is mandatory because stock-based compensation equals 23.1% of revenue and 77.3% of reported free cash flow. On that basis, today's entry is 476× and the base-case exit multiple is 25 times, within the 20-to-30-times band for the enterprise software archetype. The estimated value in five years is $66 per share.

The margin of safety

No margin of safety: the price already discounts a demanding scenario. Against the price of $263, the base case's estimated return is -24% annually and the verdict is Overvalued. The adverse scenario returns -24% annually and the favorable one -24%: the range is wide because the value depends almost entirely on a margin expansion that has not yet occurred. The maximum price to demand a 15% annual return is -708%.

What to watch

The disconfirming test is stock-based compensation measured against revenue. It held between 21% and 23% over the last three fiscal years and over the trailing twelve months (it was 23.5% in fiscal 2023), and the entire base-case thesis rests on it falling toward 14% while revenue doubles. If the stock-based expense grows at the pace of revenue, owner cash flow stays where it has been for three years, and the multiple paid today has nowhere to amortize from.

Educational / informational. Does not constitute investment advice.

Other companies of the same type